Taiwanese drug developer Senhwa Biosciences said Sunday that its investigational drug for the treatment of severe COVID-19 infections has received positive reviews from an independent monitoring group in the United States, and its clinical trials can go forward.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Bypass bridge to Guangfu Township intact after flood: Officials
10/22/2025 10:56 AM - Society
Taiwan headline news
10/22/2025 09:53 AM - Business
Taiwan shares open lower
10/22/2025 09:21 AM - Society
- Sports
Brothers shut out Monkeys in CPBL Taiwan Series Game 3, trail 1-2
10/21/2025 09:57 PM